glp 1 kidney GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal GLP-1 mediated diuresis and natriuresis

Cardiomyocytes from patients with diabetes are highly susceptible to lipid peroxide accumulation and redox dysregulation, which are highly correlated with the intrinsic mechanism of ferroptosis

In addition, by using AlzDatas Differential Expression module, the normalized expression of targets of FRP against AD in control and AD groups of the GEO dataset were analyzed

Lastly but not least, oral GLP-1 receptor agonists would be the most favorable and acceptable option as a substitute for injection therapy, as discussed below

* FOR ~15% REDUCTION IN PER PRESCRIPTION NET COST FOR GLP-1S IN 2026: CVS Health Analytics, 2026.

Ozgocmen S, Kaya H, Fadillioglu E, Aydogan R, Yilmaz Z

& Meshkani, R